Eric S. Daar, MD; Camlin Tierney, PhD; Margaret A. Fischl, MD; Paul E. Sax, MD; Katie Mollan, MS; Chakra Budhathoki, PhD; Catherine Godfrey, MD; Nasreen C. Jahed, MPH; Laurie Myers, MS; David Katzenstein, MD; Awny Farajallah, MD; James F. Rooney, MD; Keith A. Pappa, PharmD; William C. Woodward, DO; Kristine Patterson, MD; Hector Bolivar, MD; Constance A. Benson, MD; Ann C. Collier, MD; for the AIDS Clinical Trials Group Study A5202 Team
Portions of this study were presented at the 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 16–19 February 2010.
Note: The human subjects committees of all sites approved the study A5202 protocol, and written informed consent was obtained from all participants in adherence to the human experimentation guidelines of the U.S. Department of Health and Human Services.
Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.
Acknowledgment: The authors thank the patients for their participation in this study. Abbott Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline provided the study medications.
Grant Support: By award U01AI068636 from the National Institute of Allergy and Infectious Diseases, along with the previous grant for the AIDS Clinical Trials Group Central Group (AI38858) and the Statistical Data Management Center grants (AI38855 and AI68634). The study was supported in part by the General Clinical Research Center Units, funded by the National Center for Research Resources.
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-1780.
Reproducible Research Statement:Study protocol, statistical code, and data set: Available through written agreement with the Division of AIDS.
Requests for Single Reprints: Eric S. Daar, MD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, N-24, Torrance, CA 90502; e-mail, EDaar@LABioMed.org.
Current Author Addresses: Dr. Daar: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, N-24, Torrance, CA 90502.
Dr. Tierney: Harvard School of Public Health, FXB Building, Room 611, 651 Huntington Avenue, Boston, MA 02115-6017.
Drs. Fischl and Bolivar: University of Miami, 1800 Northwest 10th Avenue, Miami, FL 33136.
Dr. Sax: Brigham and Women's Hospital, 75 Francis Street, PBBA4, Boston, MA 02115.
Ms. Mollan: Harvard School of Public Health, FXB Building, Room 619, 651 Huntington Avenue, Boston, MA 02115.
Dr. Budhathoki: Harvard School of Public Health, FXB Building, Room 604C, 651 Huntington Avenue, Boston, MA 02115.
Dr. Godfrey: National Institutes of Health, Division of Acquired Immunodeficiency Syndrome, HIV Research Branch, 6700-B Rockledge Drive, MSC 7624, Bethesda, MD 20892-7624.
Mr. Jahed: Social & Scientific Systems, 8757 Georgia Avenue, 12th Floor, Silver Spring, MD 20910-3714.
Ms. Myers: Frontier Science & Technology Research Foundation, 4033 Maple Road, Amherst, NY 14226-1056.
Dr. Katzenstein: Stanford University, Center for AIDS Research, Division of Infectious Disease, S156, 300 Pasteur Drive, Stanford, CA 94305-5107.
Dr. Farajallah: Bristol-Myers Squibb Pharmaceutical Company, U.S. Pharmaceuticals, Virology Medical Affairs, 777 Scudders Mill Road, Room 1006, Plainsboro, NJ 08536.
Dr. Rooney: Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404.
Dr. Pappa: GlaxoSmithKline, Infectious Diseases Medicine Development Center, North America HIV Collaborative Studies, 5 Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398.
Dr. Woodward: Abbott Laboratories, Antiviral Global Project Team, 21 Pacific Avenue, Sinking Spring, PA 19608.
Dr. Patterson: Wake County Health and Human Services Clinical Research Site, Medicine-Infectious Diseases, 130 Mason Farm Road, Suite 2100, Bioinformatics Building, Chapel Hill, NC 27599-7215.
Dr. Benson: University of California, San Diego, Division of Infectious Diseases, 200 West Arbor Drive, Mail Code #8208, San Diego, CA 92103-8208.
Dr. Collier: University of Washington, Harborview Medical Center, Box 359929, 325 9th Avenue, Seattle, WA 98104.
Author Contributions: Conception and design: E.S. Daar, C. Tierney, M.A. Fischl, P.E. Sax, C. Godfrey, N.C. Jahed, D. Katzenstein, J.F. Rooney, K.A. Pappa, W.C. Woodward, A.C. Collier.
Analysis and interpretation of the data: E.S. Daar, C. Tierney, M.A. Fischl, P.E. Sax, K. Mollan, C. Budhathoki, C. Godfrey, D. Katzenstein, A. Farajallah, J.F. Rooney, K.A. Pappa, W.C. Woodward, C.A. Benson, A.C. Collier.
Drafting of the article: E.S. Daar, C. Tierney, M.A. Fischl, P.E. Sax, C. Budhathoki, C. Godfrey, N.C. Jahed, J.F. Rooney, C.A. Benson.
Critical revision of the article for important intellectual content: E.S. Daar, C. Tierney, M.A. Fischl, P.E. Sax, C. Budhathoki, C. Godfrey, N.C. Jahed, L. Myers, A. Farajallah, J.F. Rooney, K.A. Pappa, W.C. Woodward, K. Patterson, H. Bolivar, C.A. Benson, A.C. Collier.
Final approval of the article: E.S. Daar, C. Tierney, M.A. Fischl, P.E. Sax, C. Godfrey, N.C. Jahed, L. Myers, D. Katzenstein, A. Farajallah, J.F. Rooney, K.A. Pappa, W.C. Woodward, K. Patterson, H. Bolivar, C.A. Benson, A.C. Collier.
Provision of study materials or patients: E.S. Daar, M.A. Fischl, P.E. Sax, A. Farajallah, J.F. Rooney, K.A. Pappa, K. Patterson, H. Bolivar, C.A. Benson, A.C. Collier.
Statistical expertise: C. Tierney, K. Mollan, C. Budhathoki, J.F. Rooney, K. Patterson.
Obtaining of funding: E.S. Daar, D. Katzenstein, J.F. Rooney, W.C. Woodward, C.A. Benson.
Administrative, technical, or logistic support: C. Godfrey, N.C. Jahed, L. Myers, D. Katzenstein, J.F. Rooney, C.A. Benson.
Collection and assembly of data: E.S. Daar, M.A. Fischl, P.E. Sax, L. Myers, D. Katzenstein, J.F. Rooney, H. Bolivar, C.A. Benson, A.C. Collier.
Participating centers and individuals are listed in the Appendix.
Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, et al. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1: A Randomized Trial. Ann Intern Med. 2011;154:445-456. doi: 10.7326/0003-4819-154-7-201104050-00316
Download citation file:
Published: Ann Intern Med. 2011;154(7):445-456.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Infectious Disease, HIV, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only